Our results divulged that breast cancer, leukemia and colorectal carcinomas were the most sensitive cancer cell types to ARQ 092 and that cell lines bearing PIK3CA/PIK3R1 mutations were more responsive to ARQ 092 (53%) compared to cells containing WT-PIK3CA/PIK3R1 (24%). This evidence concerns the gene PIK3R1 and breast carcinoma.